Natasha Leskovsek

Cooley advised SiteOne Therapeutics, a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, on its acquisition by Eli Lilly.

Cooley advised Blue Owl Capital (NYSE: OWL), an asset manager redefining alternatives, on an up to $262.5 million term loan facility for ITM Isotope Technologies Munich SE, a radiopharmaceutical biotech company dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors.

Cooley advised BioMarin Pharmaceutical (Nasdaq: BMRN), a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient, on its definitive agreement to acquire Inozyme Pharma for $4 per share in an all-cash transaction valued at approximately $270 million.

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck KGaA, Darmstadt, Germany for the commercialization in mainland China of SHR7280, an oral small-molecule gonadotropin-releasing hormone receptor antagonist, for indications including medical-assisted reproduction and gynecology.

Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis.